-
Feb 25, 2022
Tuesday, March 1, 2022, 12:40-1:30 pm
-
Feb 23, 2022
We are happy to welcome Laszlo Forgacs, PharmD from Semmelweis University Hungary in our group to present his work titled “Novel approaches in pharmaceutical technology, development and molecular imaging; Development of a multimodal Prussian Blue nanotheranostic agent”.
-
Feb 14, 2022
Congratulations to Dr. Carin Helfer (PI) and Dr. Catrina Kornish (co-PI) who won a CFAES IGPaward of $50,000 for their proposal titled “Creating Sustainable, Designer Domestic Rubber”.The goal of this research proposal is to determine if genetic modifications made to guayule that resulted in changes in both macromolecular structure and physical properties will transfer to rubber dandelion and lead to similar changes in rubber macromolecular structure and performance.
-
Feb 11, 2022
Kristof will present our work on folate-targeted PEGylated doxorubicin.
-
Jan 22, 2022
Abstract: The effect of reaction conditions on the structure of poly(3,6-dioxa-1,8-octanedithiol) (polyDODT) made by Reversible Radical Recombination Polymerization (R3P) using triethylamine (TEA), H2O2 and air was investigate
-
Jan 20, 2022
-
Nov 16, 2021
Since 2011, the world’s leading academic inventors have gathered at NAI’s Annual Meetings to connect, learn, and be inspired! Over 400 distinguished inventors were there at the 2021 meeting.
-
Oct 31, 2021
Dr. Puskas and Dr. Helfer attended the conference to meet industrial and academic partners to convene a discussion of paths forward to accelerate the commercial deployment of domestic sources of natural rubber.
-
Oct 10, 2021
Our group has participated in the International Elastomer Conference organized by the Rubber Division of the American Chemical Society. Dr. Puskas gave the plenary lecture titled “Frontiers of Rubber Synthesis/Manufacturing” in the Frontiers of Rubber Science: Rubber Synthesis Session co-organized and co-moderated by Dr. Helfer.
-
Oct 8, 2021
Abstract: This paper focuses on preliminary in vitro and in vivo testing of new bivalent folate-targeted PEGylated doxorubicin (DOX) made by modular chemo-enzymatic processes (FA2-dPEG-DOX2). A unique feature is the use of monodisperse PEG (dPEG).